J. Vermette

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

J. Tabernero, K. Kern, H. Soares, 2017, Targeted Oncology.

APhase I Study with Neratinib ( HKI-272 ) , an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor , in Patients with Solid Tumors

Suzanne F. Jones, M. Ellis, Kwok-Kin Wong, 2009 .

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

K. Pierce, J. Vermette, C. Abboud, 2018, Leukemia & lymphoma.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Yan Sun, Luc Y Dirix, Zefei Jiang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Suzanne F. Jones, M. Ellis, P. Jänne, 2009, Clinical Cancer Research.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Sung-Bae Kim, C. Geyer, J. Bonneterre, 2013, European journal of cancer.

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

Craig B. Davis, A. Oza, M. Birrer, 2016, Gynecologic oncology.

S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.

C. Geyer, J. Bonneterre, J. Vermette, 2011 .